ePlus Releases New Version of Comprehensive Managed

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ePlus Releases New Version of Comprehensive Managed Services Dashboard

HERNDON, Va., Aug. 09, 2016 (GLOBE NEWSWIRE) -- ePlus inc. (NASDAQ: PLUS ) today announced that it has extended its Managed Services platform with an upgraded dashboard, featuring new functionality that provides global trending data, mapping, and managed data aggregation.  Offered as an integrated component for all ePlus Managed Services customers at no additional cost, the dashboard provides a real-time view of a customer’s heterogeneous IT environment monitored by ePlus, through a single tool accessible from a wide variety of devices.

The ePlus Managed Services dashboard, a standard feature of ePlus’ comprehensive suite of Managed Services, provides an intuitive graphical user interface that displays:

  • Aggregated metrics and health status of all components monitored by ePlus (including storage, servers, unified communications, wireless, switches, routers, and firewalls, among others )
  • Convenient drill-down capability for more expansive views
  • Global infrastructure resource utilization and trending information across multiple types of devices on one screen
  • Geographic locations and status
  • Topology maps and dynamic device connections (to the port level),  to aid in remediation and troubleshooting
  • Incident, problem, and change ticket trending and access

“With the rapid pace of change, shrinking budgets, and reductions in staff, IT departments need quick, reliable access to data analytics to manage their infrastructure,” said Dan Farrell, senior vice president of national services, ePlus.  “We’ve responded directly to our customers’ concerns and designed the dashboard as a single toolset to aggregate all managed data and provide the intelligence IT departments need to maximize efficiencies and make informed resource and budgeting decisions.”

About ePlus Managed Services

ePlus Managed Services help enterprises cost-effectively monitor, control, and proactively manage their IT infrastructure, and off-load a significant burden of day-to-day IT tasks to optimize internal IT operations and mitigate risk.  ePlus has delivered Managed Services for more than 10 years to a wide range of customers across multiple industry verticals through its 24/7/365 Managed Services Centers. Visit www.ePlus.com/ManagedServices/Pages/default.aspx for more information.

About ePlus inc.

ePlus is an engineering-centric technology solutions provider that helps organizations imagine, implement, and achieve more from their technology.  With the highest certifications from top technology partners and expertise in key technologies from data center to security, cloud, and collaboration, ePlus transforms IT from a cost center to a business enabler.  Founded in 1990, ePlus has more than 1,000 associates serving a diverse set of customers nationally, and in Europe.  The Company is headquartered at 13595 Dulles Technology Drive, Herndon, VA, 20171.  For more information, visit www.eplus.com , call 888-482-1122, or email info@eplus.com .  Connect with ePlus on Facebook at www.facebook.com/ePlusinc and on Twitter at www.twitter.com/ePlus .   ePlus. Where Technology Means More ® .

ePlus ® , Where Technology Means More ® , and ePlus products referenced herein are either registered trademarks or trademarks of ePlus inc. in the United States and/or other countries.  The names of other companies, products, and services mentioned herein may be the trademarks of their respective owners.

Statements in this press release that are not historical facts may be deemed to be “forward-looking statements.”  Actual and anticipated future results may vary materially due to certain risks and uncertainties, including, without limitation, possible adverse effects resulting from financial market disruption and general slowdown of the U.S. economy such as our current and potential customers delaying or reducing technology purchases, increasing credit risk associated with our customers and vendors, reduction of vendor incentive programs, and restrictions on our access to capital necessary to fund our operations; our ability to consummate and integrate acquisitions; the possibility of goodwill impairment charges in the future; significant adverse changes in, reductions in, or losses of relationships with major customers or vendors; the demand for and acceptance of, our products and services; our ability to adapt our services to meet changes in market developments; our ability to implement comprehensive plans for the integration of sales forces, cost containment, asset rationalization, systems integration and other key strategies; our ability to reserve adequately for credit losses; our ability to secure our electronic and other confidential information; future growth rates in our core businesses; the impact of competition in our markets; the possibility of defects in our products or catalog content data; our ability to adapt to changes in the IT industry and/or rapid change in product standards; our ability to realize our investment in leased equipment; our ability to hire and retain sufficient qualified personnel; and other risks or uncertainties detailed in our reports filed with the Securities and Exchange Commission.  All information set forth in this press release is current as of the date of this release and ePlus undertakes no duty or obligation to update this information.

Contact: Kleyton Parkhurst, SVP ePlus inc. kparkhurst@eplus.com 703-984-8150

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 229

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading

Top 5 Most Recently Viewed Articles

SoftBank Expands AI Infrastructure with DigitalBridge Deal

Updated Category News Views 109

SoftBank's Strategic Move in AI Infrastructure SoftBank Group Corp. has recently announced its plans to acquire DigitalBridge Group Inc. in a cash deal worth approximately $4 billion. This move is seen as a pivotal step in SoftBank's commitment to scaling its infrastructure capabilities for artificial intelligence globally. Details of the Acquisition Under the terms of...

Continue Reading
Nio's Bold Moves in the EV Space: What Investors Should Know

Updated Category News Views 158

Forget the Noise, Nio's Got a Game Plan Back in my day, when you heard whispers about a new product launch, it was either a cause for celebration or a catastrophe waiting to happen. Nio, the fast-rising EV player from China, is set to drop its ES9 SUV this May, and trust me, eyes are on the road. They’ve laid out the details like a clear roadmap. Mark Your Calendars Qin...

Continue Reading
Graycliff Partners Declares Landmark Structures Sale to Cerberus

Updated Category News Views 166

Graycliff Partners Announces the Sale of Landmark Structures Graycliff Partners LP has revealed its decision to sell Landmark Structures, an esteemed provider of water and industrial storage infrastructure solutions, to Cerberus Capital Management, a robust investment firm with a global reach. Landmark Structures specializes in designing, manufacturing, and installing...

Continue Reading
Wedbush Recognizes Uber Technologies as a Top Investment

Updated Category News Views 229

Wedbush Identifies Uber Technologies as a Prime Investment Opportunity In a recent analysis, Wedbush has included Uber Technologies Inc (NYSE: UBER) in its prestigious 'best ideas list.' This recognition stems from the company's attractive risk/reward dynamics, particularly as its shares are trading at a lower multiple. Valuation Insights Currently, Uber's stock is...

Continue Reading
Ververica Enhances Global Impact Through Innovative Partnerships

Updated Category News Views 161

Ververica's Global Influence in Real-Time Data Streaming Ververica, the pioneers behind Apache Flink®, recently highlighted its expanding global impact during the Flink Forward Jakarta event. This flagship occasion, known for focusing on cutting-edge data streaming technologies, served as an excellent platform for Ververica to demonstrate its dedication to helping...

Continue Reading